Department of Biochemistry, Sri Krishnadevaraya University, Anantapur, A.P, India.
J Mol Model. 2010 Aug;16(8):1357-67. doi: 10.1007/s00894-010-0653-4. Epub 2010 Feb 7.
Tuberculosis (TB) is still a major public health problem, compounded by the human immunodeficiency virus (HIV)-TB co-infection and recent emergence of multidrug-resistant (MDR) and extensively drug resistant (XDR)-TB. In this context, aspartokinase of mycobacterium tuberculosis has drawn attention for designing novel anti-TB drugs. Asp kinase is an enzyme responsible for the synthesis of 4-phospho-L-aspartate from L-aspartate and involved in the branched biosynthetic pathway leading to the synthesis of amino acids lysine, threonine, methionine and isoleucine. An intermediate of lysine biosynthetic branch, mesodiaminopimelate is also a component of the peptidoglycan which is a component of bacterial cell wall. To interfere with the production of all these amino acids and cell wall, it is possible to inhibit Asp kinase activity. This can be achieved using Asp kinase inhibitors. In order to design novel Asp kinase inhibitors as effective anti-TB drugs, it is necessary to have an understanding of the binding sites of Asp kinase. As no crystal structure of the enzyme has yet been published, we built a homology model of Asp kinase using the crystallized Asp kinase from M. Jannaschii, as template structures (2HMF and 3C1M). After the molecular dynamics refinement, the optimized homology model was assessed as a reliable structure by PROCHECK, ERRAT, WHAT-IF, PROSA2003 and VERIFY-3D. The results of molecular docking studies with natural substrates, products and feedback inhibitors are in agreement with the published data and showed that ACT domain plays an important role in binding to ligands. Based on the docking conformations, pharmacophore model can be developed by probing the common features of ligands. By analyzing the results, ACT domain architecture, certain key residues that are responsible for binding to feedback inhibitors and natural substrates were identified. This would be very helpful in understanding the blockade mechanism of Asp kinase and providing insights into rational design of novel Asp kinase inhibitors for M.tuberculosis.
结核病(TB)仍然是一个主要的公共卫生问题,加上人类免疫缺陷病毒(HIV)-TB 合并感染以及最近出现的耐多药(MDR)和广泛耐药(XDR)-TB,情况更加复杂。在这种情况下,结核分枝杆菌天冬氨酸激酶引起了人们设计新型抗结核药物的关注。天冬氨酸激酶是一种负责从天冬氨酸合成 4-磷酸-L-天冬氨酸的酶,参与导致赖氨酸、苏氨酸、蛋氨酸和异亮氨酸合成的支链生物合成途径。赖氨酸生物合成分支的中间产物,中间二氨基庚二酸也是肽聚糖的组成部分,肽聚糖是细菌细胞壁的组成部分。为了干扰所有这些氨基酸和细胞壁的产生,可以抑制天冬氨酸激酶的活性。这可以通过使用天冬氨酸激酶抑制剂来实现。为了设计新型天冬氨酸激酶抑制剂作为有效的抗结核药物,有必要了解天冬氨酸激酶的结合位点。由于尚未发表该酶的晶体结构,我们使用已结晶的来自 M. Jannaschii 的天冬氨酸激酶作为模板结构(2HMF 和 3C1M)构建了天冬氨酸激酶的同源模型。经过分子动力学精修后,通过 PROCHECK、ERRAT、WHAT-IF、PROSA2003 和 VERIFY-3D 评估优化后的同源模型是可靠的结构。与天然底物、产物和反馈抑制剂的分子对接研究结果与已发表的数据一致,并表明 ACT 结构域在与配体结合中起重要作用。基于对接构象,可以通过探测配体的共同特征来开发药效基团模型。通过分析结果,确定了 ACT 结构域结构、负责与反馈抑制剂和天然底物结合的某些关键残基。这将非常有助于理解天冬氨酸激酶的阻断机制,并为设计针对结核分枝杆菌的新型天冬氨酸激酶抑制剂提供深入的见解。